Is Tvardi Therapeutics going out of business?

Tvardi Therapeutics, Inc. (TVRD) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Tvardi Therapeutics, Inc. (TVRD) scores 18 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 72.87% (YoY)

Five questions, kept separate

Survival - Critical

3-5 mo of estimated runway from 2026-06-30, based on $15.8M of cash and short-term investments against $44.4M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

121.9% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 72.87% (YoY)
• Debt / Equity: -1.86x (Net Cash)
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue CAGR (3Y): -100.00%
• Return on Assets: -103.98%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-14.

Price as of 2026-09-07.